Roche: disappointing results in ulcerative colitis
(CercleFinance.com) - Roche reports disappointing results from its Phase III trial program evaluating its investigational drug etrolizumab in patients suffering from moderately to severely active ulcerative colitis.
The pharmaceutical company said that mixed results were observed in studies evaluating it as an inductive therapy and that studies evaluating it as a maintenance therapy failed to meet their primary endpoints.
However, Roche adds that a pivotal Phase III study is underway on etrolizumab in Crohn's disease, and that it is currently investigating other investigational drugs in inflammatory bowel diseases.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The pharmaceutical company said that mixed results were observed in studies evaluating it as an inductive therapy and that studies evaluating it as a maintenance therapy failed to meet their primary endpoints.
However, Roche adds that a pivotal Phase III study is underway on etrolizumab in Crohn's disease, and that it is currently investigating other investigational drugs in inflammatory bowel diseases.
Copyright (c) 2020 CercleFinance.com. All rights reserved.